Document is current

Article History

Received: 1 March 2025

Accepted: 2 May 2025

First Online: 14 May 2025

Declarations

:

: The study was approved by the institutional review board at OSU and was conducted in compliance with the Declaration of Helsinki.

: PT: Honoraria/consulting/ad boards for Seagen, Pfizer, Abbvie, Bristol-Myers Squibb, TG Therapeutics, ADC Therapeutics, Genentech, GenMab and Lilly USA NSG: Research funding: Regeneron, Cabaletta, BMS, Affimed, Poseida. Honoraria/consulting ad boards for ADC Therapeutics, Genentech, Novartis, BMS, Regeneron. RK: Advisory Board: BMS, Miltenyi, Abbvie, Genmab, Lilly USA, Genentech/Roche; Grants/Research Support: BMS. Speakers Bureau: AstraZeneca, BeiGene, Morphosys/Incyte BC: Research funding: Genentech, Acerta, Millenium, Bristol-Myers Squibb, F Hoffman-La Roche; Advisory Board: Incyte, AstraZeneca SKB: Honoraria: Acrotech, Affimed, Daiichi Sankyo, Kyowa Kirin, Janssen, Seagen PRG: Consultancy services: Kite/Gilead Pharma, Bristol Myers Squibb (BMS). Advisory board: Pharmacyclics LLC, ADC Therapeutics, Cellectar Biosciences, Ono Pharma, CRISPR therapeutics, IPSEN Biopharma, and Regeneron Pharmaceuticals. NLB: Research funding: ADC Therapeutics, Autolus, BMS, Celgene, Forty Seven, Genentech, Immune Design, Janssen, Merck, Millennium, Pharmacyclics, Affirmed Therapeutics, Dynavax, Gilead, MedImmune, Novartis; Consulting/Ad board: Kite Pharma, Pfizer, ADC Therapeutics, Roche/Genentech, Seattle Genetics, BTG, Acerta AJO: Genmab; Precision Bio; Adaptive Biotechnologies; Celldex; Acrotech Biopharma; Schrodinger; TG Therapeutics; Genentech. NE: Research funding (institutional): Beigene, Lilly, ADC Therapeutics, Ipsen and Incyte; Speakers Bureau for Beigene and Genetech, Ad boards for Ipsen and CRISPR Therapeutics.